您的位置: 首页 > 农业专利 > 详情页

MODULATION OF CELL FUNCTION FOR IMMUNOTHERAPY
专利权人:
Innovative Cellular Therapeutics Co.; Ltd.
发明人:
Zhiyuan Cao,Chengfei Pu,Lei Xiao,Zhao Wu
申请号:
US16555198
公开号:
US20200069732A1
申请日:
2019.08.29
申请国别(地区):
US
年份:
2020
代理人:
摘要:
Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充